Match!
Drug Discovery Today
IF
6.88
Papers
4887
Papers 4915
1 page of 492 pages (4,915 results)
Newest
Natural products (NPs) are specialized metabolites from natural sources, such as plants, animals, fungi, and bacteria, that have had an important role in the discovery and development of new drugs. For many years, bioassay-guided isolation has been the most used strategy for the isolation of bioactive NPs. Chemometrics is the science of relating the measurements made in a system or chemical process to the application of mathematical and statistical methods. Recently, chemometric techniques have ...
The advanced therapy medicinal products (ATMPs) landscape is entirely different from classical drug development. Academia has been the major source of ATMP development, and academic hospitals act as trial sites for the clinical testing of ATMPs, including early academic-led trials as well as industry-sponsored trials that pursue the full developmental pathway to market authorization. The recent breakthrough developments in some ATMPs, such as genetically engineered immune cells, have confronted ...
#1Ruili Huang (NIH: National Institutes of Health)H-Index: 34
#2Hu Zhu (NIH: National Institutes of Health)H-Index: 9
Last.Mathew D. Hall (NIH: National Institutes of Health)
view all 0 authors...
The National Center for Advancing Translational Sciences (NCATS) Pharmaceutical Collection (NPC), a comprehensive collection of clinically approved drugs, was made a public resource in 2011. Over the past decade, the NPC has been systematically profiled for activity across an array of pathways and disease models, generating an unparalleled amount of data. These data have not only enabled the identification of new repurposing candidates with several in clinical trials, but also uncovered new biol...
#1Mohammad Norouzi (UM: University of Manitoba)H-Index: 4
#2Mehrnaz Amerian (UT: University of Tehran)
Last.Fatemeh Atyabi (Tehran University of Medical Sciences)H-Index: 38
view all 0 authors...
Cancer incidence and mortality are rapidly growing worldwide. In attempts to develop more efficacious therapeutic regimens for patients with cancer, nanomedicines have found increasing applications. Findings reveal that nanomedicines improve the clinical outcomes of cancer treatment by virtue of modified pharmacokinetics (PK) and biodistributions of the bioactive agents while reducing their systemic toxicity and adverse effects. Here, we provide an update on cancer nanomedicines that have been c...
#1Shaoyong Lu (SJTU: Shanghai Jiao Tong University)H-Index: 17
#2Yuran Qiu (SJTU: Shanghai Jiao Tong University)
Last.Jian Zhang (SJTU: Shanghai Jiao Tong University)H-Index: 81
view all 0 authors...
Allosteric drugs have several significant advantages over traditional orthosteric drugs, encompassing higher selectivity and lower toxicity. Although allosteric drugs have potential advantages as therapeutic agents to treat human diseases, allosteric drug-resistance mutations still occur, rendering these drugs ineffective. Here, we review the emergence of allosteric drug-resistance mutations with an emphasis on examples covering clinically important therapeutic targets, including Breakpoint clus...
#1Fakhara Sabir (University of Szeged)
#2Ruba Ismail (University of Szeged)H-Index: 1
Last.Ildikó Csóka (University of Szeged)H-Index: 9
view all 0 authors...
Glioblastoma (GBM) is one of the most devastating and deadly types of tumor. Among all the present treatment strategies, the utmost prerequisite is prolonged intervention at the malignant site. The blood–brain barrier (BBB) is the bottleneck in the delivery of anti-GBM drugs and invasive treatment comes with many pitfalls. This review will discuss the potential of embedding antitumor drugs into nanocarriers for intranasal delivery. Additionally, it emphasizes the significance of applying quality...
#1Sanjay Kulkarni (Manipal University)
#2Abhijeet P. Pandey (Manipal University)H-Index: 8
Last.Srinivas Mutalik (Manipal University)H-Index: 24
view all 0 authors...
Here, we focus on nanoparticle (NP)-based platforms for the targeted therapy of haematological malignancies (HMs), providing an overview of surface-modified nanoplatforms, such as aptamer-, metal-, nucleic acid-, toxin, and peptide-modified NPs, for the efficient targeting of tumor cells. We discuss NPs targeting subcellular compartments, including mitochondria, nucleus and Golgi apparatus, for enhanced therapy of HMs. We also review stimuli-responsive nanoplatforms for modulating site-specific ...
#1Natasha L. Grimsey (University of Auckland)H-Index: 9
#2Juha R. Savinainen (University of Eastern Finland)H-Index: 17
Last.Muneer Ahamed (UQ: University of Queensland)H-Index: 8
view all 0 authors...
Endocannabinoid degrading enzymes regulate the concentrations of a variety of biomolecules, many of which are consequential in clinical pathologies. Monoacylglycerol lipase (MAGL) is the major enzyme involved in endocannabinoid (2-AG) hydrolysis. There is considerable interest in exploiting the therapeutic potential of MAGL in several central nervous system (CNS) disorders. The versatility, sensitivity and quantitative nature of positron emission tomography (PET) makes it ideal for functional im...
12345678910